In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CureTech, Ltd.

Latest From CureTech, Ltd.

BioNTech Gets In On ADC Action With DualityBio Licensing Deal

The German biotech is spending some of its pandemic capital on two antibody-drug conjugate candidates from the Chinese firm, including one in Phase II development.

Deals Cancer

Ferring Reflects On Fruitful 2022 As Filing Costs Hit Profits

While reproductive medicine and maternal health remains the mainstay for the Swiss group, Ferring president Per Falk says the approvals of the microbiome treatment Rebyota and bladder cancer gene therapy Adstiladrin represent "important avenues for exploration and growth."

Sales & Earnings Business Strategies

The Top Five Pharma Stories Of 2022

Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.

Scrip Perspectives M & A

Finance Watch: Early VC Forecast Predicts Reduced Investment In 2023

Private Company Edition: Pitchbook is out with an early look at its venture capital expectations for next year, showing continued interest in seed financings and fewer $100m-plus mega-rounds. Recent VC deals include a $75m series B financing for Alpha-9 Theranostics and $71.6m for A2 Biotherapeutics. 

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register